Non-Helicobacter Pylori Stomach Ulcers
Non-H. pylori gastric ulcers account for approximately 30-40% of all peptic ulcers, with NSAIDs being the predominant cause, followed by a smaller subset of truly idiopathic ulcers that require long-term proton pump inhibitor therapy and careful exclusion of underlying pathology.
Causes and Epidemiology
The landscape of non-H. pylori ulcers has evolved significantly. When you encounter an H. pylori-negative ulcer, work through this systematic approach:
Primary Causes (in order of frequency):
1. NSAID/Aspirin Use (60-70% of non-H. pylori ulcers) 1
- Question patients carefully about all NSAID use, including over-the-counter medications
- Consider surreptitious use
- The combination of H. pylori infection and NSAIDs synergistically increases bleeding risk more than sixfold 2
2. Truly Idiopathic Ulcers (approximately 11-30%) 1, 3
- These patients characteristically have:
- Critical caveat: Non-H. pylori ulcers associate with higher rebleeding rates and higher overall mortality compared to H. pylori-positive disease 3
3. Rare but Important Causes to Exclude:
- Gastrinoma (Zollinger-Ellison syndrome) - check fasting gastrin level 6
- Gastric malignancy/lymphoma - mandatory biopsies 6
- Crohn's disease - obtain biopsies of ulcer and surrounding mucosa 6, 5
- Unusual infections - consider in immunocompromised patients 6
Diagnostic Approach
Step 1: Confirm True H. pylori-Negative Status
Common pitfall: False-negative H. pylori testing occurs frequently in acute bleeding due to:
- Recent antibiotic use
- Bismuth preparations
- Proton pump inhibitor therapy 7
Recommended strategy 7:
- Test for H. pylori during acute presentation
- If negative, repeat confirmatory testing after the acute bleeding episode
- Use urea breath test (sensitivity 88-95%, specificity 95-100%) or stool antigen test (sensitivity 94%, specificity 92%) 8
Step 2: Obtain Tissue Diagnosis
Mandatory endoscopic biopsies should include 6:
- Multiple samples from the ulcer itself (to exclude malignancy)
- Surrounding gastric mucosa
- Duodenal mucosa if duodenal ulcer present
- Specific testing for H. pylori on biopsy specimens
Step 3: Exclude Hypersecretory States
For unexplained ulcers, particularly if multiple or refractory:
- Measure fasting serum gastrin level
- Consider secretin stimulation test if gastrinoma suspected 6
Treatment Strategy
Acute Management
For bleeding non-H. pylori ulcers 7, 9:
High-dose PPI therapy:
Transition to oral therapy:
- After 72 hours IV therapy, switch to twice-daily oral PPI for 14 days 9
- Then continue once-daily dosing
Long-term Management
For idiopathic non-H. pylori ulcers 6, 4:
Patients require indefinite PPI maintenance therapy because:
- These ulcers are more difficult to control than H. pylori-positive ulcers 4, 5
- Antisecretory drugs are less effective in the absence of H. pylori infection 4
- Higher PPI doses may be necessary to control acid secretion and prevent relapse 6
NSAID-Associated Ulcers
If NSAIDs must be continued 11, 9:
If COX-2 inhibitor unavailable: Use ibuprofen (least damaging traditional NSAID) plus PPI 11
For patients on antiplatelet therapy:
Follow-up Requirements
Gastric ulcers 11:
- Mandatory repeat endoscopy at 6 weeks to:
- Confirm healing
- Exclude malignancy (repeat biopsies if not healed)
- Continue PPI until healing confirmed
Duodenal ulcers 11:
- Repeat endoscopy generally not necessary unless patient requires continued NSAIDs
Key Clinical Pearls
Location matters: H. pylori-positive ulcers occur more frequently on the lesser curve (76%) versus prepyloric location (60%) 1
Patient characteristics: Non-H. pylori ulcer patients are typically older, have more comorbidities, and more frequently experience bleeding while hospitalized 3
Rebleeding risk: These patients have inherently higher rebleeding rates than H. pylori-positive ulcers, requiring more aggressive acid suppression 3
Resistance to healing: Expect these ulcers to be more refractory to standard therapy; don't hesitate to escalate PPI dosing 6, 4